Title |
A Revisited Strategy for Antiepileptic Drug Development in Children
|
---|---|
Published in |
CNS Drugs, January 2013
|
DOI | 10.1007/s40263-012-0035-9 |
Pubmed ID | |
Authors |
Catherine Chiron, Behrouz Kassai, Olivier Dulac, Gerard Pons, Rima Nabbout |
Abstract |
Randomized controlled trials (RCTs) in refractory paediatric epilepsy usually involve the two main types of epilepsy shared by children and adults, focal epilepsy and Lennox-Gastaut syndrome (LGS). Most other epilepsy syndromes, specifically paediatric, are excluded from drug development. In order to identify among them the candidate(s) for dedicated RCTs with a new drug, the European Medicine Agency (EMA) recently recommended proceeding in two steps: (1) an exploratory (prospective-observational) trial (POT) including a large variety of paediatric epilepsy syndromes and (2) a subsequent RCT in each of those that disclose a signal for possible efficacy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
United States | 1 | 2% |
Unknown | 40 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 21% |
Student > Bachelor | 5 | 12% |
Student > Postgraduate | 4 | 10% |
Other | 3 | 7% |
Professor > Associate Professor | 3 | 7% |
Other | 8 | 19% |
Unknown | 10 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 33% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
Agricultural and Biological Sciences | 4 | 10% |
Psychology | 2 | 5% |
Neuroscience | 2 | 5% |
Other | 5 | 12% |
Unknown | 11 | 26% |